Aprea
Doylestown, US · 3 known investors
Find your way into Aprea
48 people in our graph share verified history with the Aprea team — schools, employers, funds. One of them is your warm intro.
Michael Kalosunlockedknows Oren Gilad · together at University of Pennsylvania School of Medicine (overlapped)
×2knows the team · via Trevena, Inc.
knows the team · via Windtree Therapeutics, Inc.
×6knows the team · via University of Pennsylvania School of Medicine
knows the team · via NephroGenex
knows the team · via DeSales University
Aprea Therapeutics is a biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways to treat solid tumors including ovarian, colorectal, prostate, and breast cancers. The company's lead programs are APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in clinical development.
Founders & leadership
JP
John P. HamillinSr. VP and Chief Financial OfficerJohn P. Hamill is an Executive Officer at Aprea Therapeutics with over 30 years of corporate finance experience across startup biotechnology firms and multinational pharmaceutical, clinical research, and specialty chemical companies, including roles as CFO/COO directing financial and investor relations functions for public and private organizations.
OG
Oren GiladinChief Executive Officer, PresidentOren Gilad is Chief Executive Officer and President of Aprea Therapeutics, a clinical-stage biopharmaceutical company developing cancer therapeutics that target DNA damage response pathways. He previously founded and served as President and CEO of Atrin Pharmaceuticals, which was acquired by Aprea, and has published research and authored patent applications in oncology.
Board
JB
Jean-Pierre BizzariBoard director
GG
Gabriela GruiaBoard director
RP
Rifat PamukcuBoard director
BS
Bernd SeizingerBoard director
MD
Marc DueyBoard director
JB
John B. HennemanBoard director
MG
Michael GrissingerBoard director
RP
Richard PetersBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$3.1M disclosed across 1 round · 2025
▶$3.1MraisedDec 2025 · 8 investors · BiotechnologyRule 506(b)
▶$3.1MraisedDec 2025 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John P. HamillExecutive Officer
- Jean-Pierre BizzariDirector
- Gabriela GruiaDirector
- Rifat PamukcuDirector
- Bernd SeizingerDirector
- Marc DueyDirector
- John B. HennemanDirector
- Oren GiladExecutive Officer, Director
- Michael GrissingerDirector
- Richard PetersDirector
- Offering amount
- $5.8M
- Amount sold
- $3.1M
- Sales commissions
- $210K
- Placement agents
- Maxim Group LLC
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $862.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Aprea Therapeutics 2Q 2026: Revenue $0 Net loss $(3.59M), EPS $(0.07) — 10-Q Summarytradingview.com · Aug 2026Frequently asked questions
- What does Aprea do?
- Aprea Therapeutics is a biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways to treat solid tumors including ovarian, colorectal, prostate, and breast cancers. The company's lead programs are APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in clinical development.
- Who are Aprea's investors?
- Aprea's investors include 5AM Ventures, HealthCap, Versant Ventures.
- How much funding has Aprea raised?
- Aprea has disclosed $3.1M raised across 1 round.
- Where is Aprea headquartered?
- Aprea is headquartered in Doylestown, US.